^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) + Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
04/04/2022
Excerpt:
Acute Lymphoblastic Leukemia...Other Recommended Regimens...Inotuzumab ozogamicins + mini-hyperCVD ± blinatumomabs (for B-ALL only) (cyclophosphamide, dexamethasone, vincristine, methotrexate, cytarabine)
Secondary therapy:
cytarabine; Mini-HCVD; vincristine; cyclophosphamide; methotrexate; dexamethasone
